Laugsch Magdalena, Rostovskaya Maria, Velychko Sergiy, Richter Cornelia, Zimmer Ariane, Klink Barbara, Schröck Evelin, Haase Michael, Neumann Katrin, Thieme Sebastian, Roesler Joachim, Brenner Sebastian, Anastassiadis Konstantinos
Department of Pediatrics, University Clinic Carl Gustav Carus, TU Dresden, Dresden, Germany.
Stem Cell Engineering, BIOTEC, TU Dresden, Dresden, Germany.
Mol Ther. 2016 Apr;24(4):812-22. doi: 10.1038/mt.2015.154. Epub 2015 Aug 28.
Chronic granulomatous disease (CGD) is an inherited immunodeficiency, caused by the inability of neutrophils to produce functional NADPH oxidase required for fighting microbial infections. The X-linked form of CGD (X-CGD), which is due to mutations in the CYBB (gp91phox) gene, a component of NADPH oxidase, accounts for about two-thirds of CGD cases. We derived induced pluripotent stem cells (iPSCs) from X-CGD patient keratinocytes using a Flp recombinase excisable lentiviral reprogramming vector. For restoring gp91phox function, we applied two strategies: transposon-mediated bacterial artificial chromosome (BAC) transgenesis and gene targeting using vectors with a fixed 5' homology arm (HA) of 8 kb and 3'HA varying in size from 30 to 80 kb. High efficiency of homologous recombination (up to 22%) was observed with increased size of the 3'HA. Both, BAC transgenesis and gene targeting resulted in functional restoration of the gp91phox measured by an oxidase activity assay in X-CGD iPSCs differentiated into the myeloid lineage. In conclusion, we delivered an important milestone towards the use of genetically corrected autologous cells for the treatment of X-CGD and monogenic diseases in general.
慢性肉芽肿病(CGD)是一种遗传性免疫缺陷病,由中性粒细胞无法产生对抗微生物感染所需的功能性NADPH氧化酶引起。X连锁型CGD(X-CGD)是由于NADPH氧化酶的一个组成部分CYBB(gp91phox)基因发生突变所致,约占CGD病例的三分之二。我们使用Flp重组酶可切除的慢病毒重编程载体从X-CGD患者角质形成细胞中获得了诱导多能干细胞(iPSC)。为了恢复gp91phox的功能,我们应用了两种策略:转座子介导的细菌人工染色体(BAC)转基因和使用具有8 kb固定5'同源臂(HA)和大小从30到80 kb不等的3'HA的载体进行基因靶向。随着3'HA大小的增加,观察到同源重组效率较高(高达22%)。BAC转基因和基因靶向都导致了在分化为髓系谱系的X-CGD iPSC中通过氧化酶活性测定法测量的gp91phox的功能恢复。总之,我们朝着使用基因校正的自体细胞治疗X-CGD和一般单基因疾病迈出了重要的一步。